Skip to content
Menu

First Tracks Biotherapeutics, Inc. TRAX

Full chart Compare
Set alert

Price alert · TRAX

All alert types
41.89 USD -2.57 (-5.78%)

As ofNov 20, 2026, 3:33 PM EST

41.61 Day range 44.51
14.72 52-week range 54.78
YTD
+120.47%
1 year
+120.47%

 

No chart data for this range yet.
Market cap
1.76B
EPS (ttm)
-4.71
Shares out
42.02M
Forward P/E
-12.84
YTD return
+120.47%
1-year return
+120.47%
50-day average
40.16
200-day average
31.90
Enterprise value
1.72B
Volume
304.89K
Avg volume
827.06K
Open
43.99
Previous close
44.46
Day's range
41.61 – 44.51
52-week range
14.72 – 54.78
Analysts
Strong Buy
Price target
75.17 (+79.4%)
Earnings date
Feb 2, 2027

Key statistics

Price / book
10.57
Total cash
155.63M
Total debt
3.77M

Fundamental scorecard

3 of 25 checks passed on TRAX’s reported financials

ValueGrowthProfitabilityHealthDividend

3of 25 checks passed

  • Value 0 of 5
  • Growth No data
  • Profitability No data
  • Financial health 3 of 5
  • Dividend No data

Statements to Sep 30, 2026.

Financials — quick view

All financials
TRAX Revenue — quarterly 0
TRAX Net income — quarterly -31.36M
TRAX EPS — quarterly -0.88

Earnings

TRAX recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 2, 2027Dec 30, 2026-0.77———
Nov 3, 2026Sep 30, 2026-0.90274-0.88+0.02+2.52%
Aug 12, 2026Jun 30, 2026-0.80256-0.95-0.15-18.37%
May 14, 2026Mar 31, 2026-0.98059-1.45-0.47-47.87%

Upgrades / downgrades

TRAX analyst upgrades and downgrades
DateFirmActionFromTo
Nov 4, 2026GuggenheimmainBuyBuy
Oct 16, 2026Leerink PartnersmainOutperformOutperform
Oct 13, 2026Canaccord GenuitymainBuyBuy
Oct 13, 2026Evercore ISI GroupmainOutperformOutperform
Oct 13, 2026Wells FargomainOverweightOverweight
Sep 30, 2026Canaccord Genuityinit—Buy

About First Tracks Biotherapeutics, Inc.

First Tracks Biotherapeutics, Inc. operates a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases in United States. Its products includes ANB033, a novel anti-CD122 antagonist that targets the shared beta subunit of the IL-15 and IL-2 receptors; Rosnilimab, a antibody engineered to selectively deplete pathogenic T cells in both the periphery and inflamed tissues; and ANB101, a BDCA2-modulating antibody designed to specifically target plasmacytoid dendritic cells (pDCs). First Tracks Biotherapeutics, Inc. was formerly known as Biopharma Co., Inc. and changed its name to First Tracks Biotherapeutics, Inc. in February 2026. First Tracks Biotherapeutics, Inc. was founded in 2019 and is based in San Diego, California.

Sector
Healthcare
Industry
Biotechnology
Country
United States

News

Your note

Sign in to keep a note on TRAX — it syncs with the Stock Master app.

Insider holders

TRAX insider holders
InsiderRelationLatest transactionDateShares held
ECOR1 CAPITAL, L.L.C.Beneficial Owner of more than 10% of a Class of SecuritySaleApr 19, 20260
FENTON DENNIS MDirectorConversion of Exercise of derivative securityJun 14, 202610,995
JAIN RITADirectorConversion of Exercise of derivative securityJun 14, 202619,194
JOE ANTHONY WAREDirectorSaleSep 1, 202615,660
MARQUET MAGDADirectorConversion of Exercise of derivative securityJun 14, 202615,960
ORWIN JOHN ADirectorConversion of Exercise of derivative securitySep 14, 202617,995

Institution ownership

TRAX institution ownership
Holder% heldSharesValueReported
EcoR1 Capital, LLC7.56%3,174,519141.14MSep 29, 2026
TCG Crossover Management, LLC6.89%2,895,304128.73MSep 29, 2026
Blackrock Inc.6.18%2,597,026115.46MSep 29, 2026
Affinity Asset Advisors, Llc4.95%2,080,00092.48MSep 29, 2026
Adage Capital Partners GP L.L.C.4.94%2,077,17992.35MSep 29, 2026
FMR, LLC4.16%1,747,17777.68MSep 29, 2026

Fund ownership

TRAX fund ownership
Holder% heldSharesValueReported
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund2.65%1,111,47049.42MJun 29, 2026
SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF2.08%874,16838.87MSep 29, 2026
iShares Trust-iShares Russell 2000 ETF2.06%865,02138.46MSep 29, 2026
Fidelity Select Portfolios-Select Health Care Portfolio1.29%540,00024.01MSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund0.74%309,28513.75MJun 29, 2026
Federated Hermes Equity Funds-Federated Hermes Kaufmann Small Cap Fund0.69%290,00012.89MJul 30, 2026